Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

VYNE Therapeutics (VYNE) Gross Profit (2019 - 2021)

VYNE Therapeutics' Gross Profit history spans 3 years, with the latest figure at -$630000.0 for Q4 2021.

  • For Q4 2021, Gross Profit fell 116.79% year-over-year to -$630000.0; the TTM value through Dec 2021 reached -$2.4 million, down 112.33%, while the annual FY2021 figure was -$2.4 million, 112.33% down from the prior year.
  • Gross Profit reached -$630000.0 in Q4 2021 per VYNE's latest filing, up from -$916000.0 in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $11.5 million in Q2 2020 to a low of -$916000.0 in Q3 2021.
  • Average Gross Profit over 3 years is $1.9 million, with a median of $135000.0 recorded in 2019.
  • Peak YoY movement for Gross Profit: soared 2679.26% in 2020, then tumbled 131.61% in 2021.
  • A 3-year view of Gross Profit shows it stood at $135000.0 in 2019, then skyrocketed by 2679.26% to $3.8 million in 2020, then plummeted by 116.79% to -$630000.0 in 2021.
  • Per Business Quant, the three most recent readings for VYNE's Gross Profit are -$630000.0 (Q4 2021), -$916000.0 (Q3 2021), and -$500000.0 (Q2 2021).